Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index
Fresenius Medical Care (FME), the global leader in renal disease products and services, has achieved a significant milestone by being included in the Dow Jones Sustainability World Index and, for the 15th time, in the Dow Jones Sustainability Europe Index. The company demonstrated notable progress in its sustainability targets across three strategic areas: healthcare quality enhancement, team building, and environmental footprint reduction.
Key achievements in 2023 include: improving patient satisfaction with a Net Promoter Score of 72, increasing women's representation in top management to 34%, and reducing Scope 1 and 2 emissions by 16% from 2020 levels. The company also signed virtual power purchase agreements for 580 gigawatt hours annually with wind and solar farms in Germany and the U.S., while submitting a commitment to the Science Based Target initiative.
Fresenius Medical Care (FME), leader globale nei prodotti e servizi per le malattie renali, ha raggiunto un traguardo significativo venendo inclusa nell'Indice di Sostenibilità Mondiale Dow Jones e, per la 15esima volta, nell'Indice di Sostenibilità Europa Dow Jones. L'azienda ha dimostrato notevoli progressi nei suoi obiettivi di sostenibilità in tre aree strategiche: miglioramento della qualità dell'assistenza sanitaria, formazione del team e riduzione dell'impatto ambientale.
Le principali realizzazioni nel 2023 includono: miglioramento della soddisfazione dei pazienti con un punteggio Net Promoter di 72, aumento della rappresentanza femminile nella alta dirigenza al 34% e riduzione delle emissioni di Ambito 1 e 2 del 16% rispetto ai livelli del 2020. L'azienda ha anche firmato accordi di acquisto di energia virtuale per 580 gigawattora all'anno con impianti eolici e solari in Germania e negli Stati Uniti, oltre a presentare un impegno per l'iniziativa Science Based Target.
Fresenius Medical Care (FME), líder mundial en productos y servicios para enfermedades renales, ha alcanzado un hito importante al ser incluida en el Índice de Sostenibilidad Mundial Dow Jones y, por decimoquinto año, en el Índice de Sostenibilidad Europa Dow Jones. La empresa ha demostrado avances notables en sus objetivos de sostenibilidad en tres áreas estratégicas: mejora de la calidad de la atención sanitaria, formación de equipos y reducción de la huella ambiental.
Los logros clave en 2023 incluyen: mejora de la satisfacción del paciente con un puntaje Net Promoter de 72, aumento de la representación femenina en la alta dirección al 34% y reducción de las emisiones de Alcance 1 y 2 en un 16% con respecto a los niveles de 2020. La empresa también firmó acuerdos de compra de energía virtual por 580 gigavatios hora anuales con parques eólicos y solares en Alemania y EE.UU., además de presentar un compromiso con la iniciativa Science Based Target.
프레제니우스 메디컬 케어 (FME)는 신장 질환 제품 및 서비스의 글로벌 리더로서 다우존스 지속 가능성 세계 지수에 포함되었고 15번째로 다우존스 지속 가능성 유럽 지수에 다시 이름을 올렸습니다. 이 회사는 세 가지 전략적 분야에서 지속 가능성 목표에 대한 주목할 만한 진전을 보였습니다: 의료 품질 향상, 팀 구성 및 환경 발자국 감소.
2023년 주요 성과로는: 환자 만족도 향상(NPS 72점), 최고 경영진 내 여성 비율 34%로 증가, 2020년 대비 Scope 1 및 2 배출량 16% 감소 등이 있습니다. 또한 이 회사는 독일과 미국의 풍력 및 태양광 발전소와 연간 580 기가와트시의 가상 전력 구매 계약을 체결하고, Science Based Target Initiative에 대한 약속을 제출했습니다.
Fresenius Medical Care (FME), leader mondial dans les produits et services pour les maladies rénales, a atteint un jalon important en étant inclus dans le Dow Jones Sustainability World Index et, pour la 15ème fois, dans le Dow Jones Sustainability Europe Index. L'entreprise a démontré des progrès notables dans ses objectifs de durabilité dans trois domaines stratégiques : amélioration de la qualité des soins de santé, développement d'équipes et réduction de l'empreinte environnementale.
Les réalisations clés en 2023 incluent : amélioration de la satisfaction des patients avec un score Net Promoter de 72, augmentation de la représentation des femmes dans la haute direction à 34 % et réduction des émissions de portée 1 et 2 de 16 % par rapport aux niveaux de 2020. L'entreprise a également signé des contrats d'achat d'énergie virtuelle pour 580 gigawattheures annuellement avec des parcs éoliens et solaires en Allemagne et aux États-Unis, tout en soumettant un engagement à l'initiative Science Based Target.
Fresenius Medical Care (FME), der weltweit führende Anbieter von Produkten und Dienstleistungen bei Nierenerkrankungen, hat einen bedeutenden Meilenstein erreicht, indem er im Dow Jones Sustainability World Index und zum 15. Mal im Dow Jones Sustainability Europe Index aufgenommen wurde. Das Unternehmen stellte bemerkenswerte Fortschritte bei seinen Nachhaltigkeitszielen in drei strategischen Bereichen fest: Verbesserung der Gesundheitsqualität, Teambildung und Reduzierung des ökologischen Fußabdrucks.
Zu den wichtigsten Erfolgen im Jahr 2023 gehören: Verbesserung der Patientenzufriedenheit mit einem Net Promoter Score von 72, Erhöhung des Anteils von Frauen im Top-Management auf 34 % und Reduzierung der Scope-1- und 2-Emissionen um 16 % im Vergleich zu den Werten von 2020. Das Unternehmen hat auch virtuelle Stromabnahmeverträge über jährlich 580 Gigawattstunden mit Wind- und Solarparks in Deutschland und den USA unterzeichnet und sich zur Science Based Target Initiative verpflichtet.
- None.
- None.
- Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and
Europe - The company recorded progress towards its sustainability targets
- Sustainability is one of the essential drivers for future
BAD HOMBURG,
Helen Giza, CEO of Fresenius Medical Care AG, said: "We believe that sustainability and excellent patient care are inextricably linked. I am very proud that our employees' commitment to our sustainability efforts has been recognized through the inclusion in the indices. Considering sustainability in our products and the way we work helps to ensure that we provide excellent, high-quality services for future generations."
Fresenius Medical Care continuously incorporates sustainability into its global business operations. The company's approach centers on three strategic focus areas:
- Enhancing quality of care and access to healthcare,
- building the best teams to serve patients, and
- reducing the company's environmental footprint.
In 2023, FME has reported progress toward its sustainability targets and governance:
- Fresenius Medical Care improved its Net Promoter Score to 72, reflecting a high patient satisfaction with its services.
- The company increased the share of women in the top two management levels below Management Board to
34% , underlining its commitment to diversity, equity and inclusion. - FME moved ahead with its climate neutrality action plan, with Scope 1 and 2 emissions in 2023 decreasing by
16% from a 2020 baseline. The reduction of CO2e emissions is included in the targets for the long-term compensation of the Management Board members for 2024. - In 2024 the company signed five virtual power purchase agreements for approximately 580 gigawatt hours per year with wind and solar farms in
Germany and theU.S. It also submitted the commitment letter to the Science Based Target initiative (SBTi).
The Dow Jones Sustainability Indices are the longest-running global sustainability benchmarks. Each year, over 13,000 companies are invited to participate in the Corporate Sustainability Assessment (CSA). Approximately 3,500 of the largest companies worldwide are eligible for inclusion in any DJSI. The annual review evaluates companies' sustainability performance in areas relevant to each industry.
An overview of Fresenius Medical Care's progress in sustainability can be found in the company's non-financial group report here.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-listed-in-the-dow-jones-sustainability-world-index-and-for-the-15th-time-in-the-dow-jones-sustainability-europe-index-302338375.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What sustainability achievements led to FMS being included in the Dow Jones Sustainability Indices?
How much renewable energy has FMS committed to through power purchase agreements in 2024?
What are the three strategic focus areas of FMS's sustainability approach?
How has FMS improved its gender diversity in management positions?
What environmental commitments has FMS made for 2024?
